This article includes a summary of the ERG report and the AC’s final decision for the FTA of pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria (PNH) in adults whose anaemia is uncontrolled after treatment with a C5 complement inhibitor. Here, C5 is linked to paroxysmal nocturnal hemoglobinuria.